title: Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
abstract: The long-term outcome of patients with haematological malignancies treated with reduced-intensity conditioned allogeneic peripheral blood stem cell transplantation is not known. We report the outcome of 79 patients with poor-risk myeloid and lymphoid malignancies transplanted with reduced-intensity conditioning (RIC) regimens. The diagnoses include AML/myelodysplastic syndrome (n=43), non Hodgkin's lymphoma (n=30), Hodgkin's lymphoma (n=3), ALL (n=2) and CML (n=1). For the entire cohort, the disease-free survival (DFS) and OS were 61.2 and 35.7%, respectively. Twenty patients relapsed, 18 within the first three years, and 14 patients succumbed to progressive disease. Overall, 31 patients died from transplant-related complications within the first three years. Day 100 non-relapse mortality correlated with a higher total nucleated cell dose in the graft (odds ratio: 3.9). For those in CR at 3 years, the DFS and OS were 84.2 and 81.1%, respectively. Furthermore, of 43 patients with active disease at the time of transplantation, 16 remained in CR after 3 years. The majority of the long-term survivors were functioning independently. One patient died from a second malignancy. No post-transplant lymphoproliferative disorder was seen. In conclusion, durable disease control was achieved after RIC allogeneic stem cell transplantation for patients with advanced myeloid and lymphoid malignancies.
authors.affiliation: Department of Malignant Haematology and Stem Cell Transplantation, Monash University and The Alfred Hospital, Melbourne, Victoria, Australia. s.patil@alfred.org.au
authors.forename: S
authors.initials: S
authors.lastname: Patil
authors.forename: A
authors.initials: A
authors.lastname: Spencer
authors.forename: A
authors.initials: A
authors.lastname: Schwarer
authors.forename: I
authors.initials: I
authors.lastname: Lewis
authors.forename: M
authors.initials: M
authors.lastname: Hertzberg
authors.forename: S
authors.initials: S
authors.lastname: Avery
authors.forename: A
authors.initials: A
authors.lastname: Wei
authors.forename: T
authors.initials: T
authors.lastname: Noutsos
authors.forename: E
authors.initials: E
authors.lastname: Paul
authors.forename: Y
authors.initials: Y
authors.lastname: Taouk
authors.forename: J
authors.initials: J
authors.lastname: Muirhead
mesh_terms: D000328:Adult; D002423:Cause of Death; D002452:Cell Count; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000401:mortality / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome